← Back to Clinical Trials
Recruiting NCT07512518

NCT07512518 Observational Cohort Study of Chronic Viral Infection in the Central Nervous System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07512518
Status Recruiting
Phase
Sponsor Peking Union Medical College Hospital
Condition Progressive Multifocal Leukoencephalopathy
Study Type OBSERVATIONAL
Enrollment 66 participants
Start Date 2023-02-20
Primary Completion 2030-10-25

Trial Parameters

Condition Progressive Multifocal Leukoencephalopathy
Sponsor Peking Union Medical College Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 66
Sex ALL
Min Age 14 Years
Max Age N/A
Start Date 2023-02-20
Completion 2030-10-25
Interventions
Immune Checkpoint Inhibitors

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This research team intends to conduct a real-world cohort study of chronic CNS viral infections represented by PML, to evaluate whether administration of immune checkpoint inhibitors improves long-term outcomes in this patient population.Patients with prior follow-up will be enrolled into a retrospective/prospective ambidirectional cohort, and newly diagnosed patients will be enrolled into a prospective cohort.

Eligibility Criteria

Inclusion Criteria: 1. Age \> 14 years old. 2. Confirmed diagnosis of chronic viral infection of the central nervous system (CNS). 3. Signed informed consent. The diagnosis of Progressive Multifocal Leukoencephalopathy (PML) shall meet one of the following criteria:(1) Neuropathological diagnosis: Pathological examination of brain tissue shows demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei; immunohistochemical detection of JC virus (JCV) antigen.(2) Clinical + imaging + cerebrospinal fluid (CSF) diagnosis: Clinical manifestations of progressive neurological dysfunction; neuroimaging shows single or multiple asymmetric white matter lesions with large volume, mostly involving the U-fibers, and rare mass effect; detection of JC virus DNA in cerebrospinal fluid. Specific reference shall be made to the 2013 American Academy of Neurology (AAN) diagnostic criteria. For the diagnosis of other chronic viral infections of the central nervous system, the clinical manifest

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology